FANCD2 as a novel prognostic biomarker correlated with immune and drug therapy in Hepatitis B-related hepatocellular carcinoma

被引:0
作者
Xiaowei Tang
Bei Luo
Shu Huang
Jiao Jiang
Yuan Chen
Wensen Ren
Xiaomin Shi
Wei Zhang
Lei Shi
Xiaolin Zhong
Muhan Lü
机构
[1] the Affiliated Hospital of Southwest Medical University,Department of Gastroenterology
[2] the People’s Hospital of Lianshui,Department of Gastroenterology
来源
European Journal of Medical Research | / 28卷
关键词
FANCD2; Hepatocellular carcinoma; Biomarker; Prognostic; Immunity;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 291 条
[1]  
Villanueva A(2019)Hepatocellular carcinoma Reply N Engl J Med 381 1264-1273.e1
[2]  
El-Serag HB(2012)Epidemiology of viral hepatitis and hepatocellular carcinoma Gastroenterology 142 1573-84.e1-2
[3]  
Singh S(2013)Liver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis Clin Gastroenterol Hepatol 11 191-9
[4]  
Fujii LL(2015)Emerging trends in hepatocellular carcinoma incidence and mortality Hepatology. 61 599-616
[5]  
Murad MH(2018)Molecular therapies and precision medicine for hepatocellular carcinoma Nat Rev Clin Oncol 15 1124-1141
[6]  
Wang Z(2019)β-catenin activation promotes immune escape and resistance to Anti-PD-1 therapy in hepatocellular carcinoma Cancer Discov. 9 2524-2529
[7]  
Asrani SK(1990)Hepatitis B- and C-related hepatocellular carcinomas yield different clinical features and prognosis European J Cancer. 42 e1904197-2208
[8]  
Ehman RL(2019)Recent progress in ferroptosis inducers for cancer therapy Adv Mater. 31 50-2388
[9]  
et, al. B(2020)Novel insights on targeting ferroptosis in cancer therapy Biomark Res 2 98-92
[10]  
Njei Y(2022)Macropinocytosis is an alternative pathway of cysteine acquisition and mitigates sorafenib-induced ferroptosis in hepatocellular carcinoma J Exp Clin Cancer Res. 41 427-248